Premium
Incidence and classification of cutaneous manifestations in rheumatoid arthritis
Author(s) -
Ziemer Mirjana,
Müller AnneKatrin,
Hein Gert,
Oelzner Peter,
Elsner Peter
Publication year - 2016
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.12680
Subject(s) - medicine , rheumatoid arthritis , leflunomide , rheumatoid nodule , rheumatology , rheumatoid factor , dermatology , vasculitis , incidence (geometry) , disease , immunology , physics , optics
Summary Background and objective There have only been few studies examining rheumatoid arthritis (RA)‐related skin manifestations in larger patient populations. Herein, we present current data on the prevalence and spectrum of cutaneous lesions in RA, addressing disease activity scores, anti‐CCP antibodies as well as novel pharmacological approaches. Patients and methods Between November 2006 and July 2007, 214 patients with RA treated at the Division of Rheumatology, University Hospital Jena, Germany, were prospectively examined. Results 27.5 % of patients exhibited RA‐related skin manifestations, almost all of which were rheumatoid nodules. These lesions occurred significantly more frequently in patients with longstanding disease, those testing positive for rheumatoid factor and anti‐CCP‐antibodies, as well as individuals on leflunomide and TNF‐alpha antagonists. Comparatively lower prevalence rates were observed for palisading neutrophilic and granulomatous dermatitis and rheumatoid vasculitis. Conclusions Despite increasingly early treatment of RA and use of novel pharmacological agents, there is a high prevalence of rheumatoid nodules, which represent the most common cutaneous manifestation in RA. The higher prevalence of rheumatoid nodules in patients on leflunomide and TNF‐alpha antagonists might be an indication that pharmacological treatment has only limited effects on their formation, possibly due to pathogenetic pathways that are only inadequately affected by drug therapies. By contrast, palisading neutrophilic and granulomatous dermatitis and rheumatoid vasculitis appear to respond better to novel pharmacological agents.